Document Detail

Perspective: does ranolazine have potential for the treatment of atrial fibrillation?
MedLine Citation:
PMID:  21105855     Owner:  NLM     Status:  In-Process    
Atrial fibrillation is the most common arrhythmia seen in clinical practice, and novel pharmacological approaches for treatment are sought. Ranolazine (Ranexa; N-(2,6-dimethylphenyl)-2-[4-(2-hydroxy-3-[2-methoxyphenoxy]propyl)piperazin-1-yl]acetamide) is used clinically for the treatment of angina pectoris. Evidence is reviewed from both pre-clinical and clinical studies, which suggests that ranolazine also exhibits antiarrhythmic activity with growing evidence for atrio-selectivity. Further work is required in order to explore more fully the potential of ranolazine in the treatment of atrial fibrillation. In particular, investigation of ranolazine actions against atrial fibrillation in animal models that incorporate atrial fibrillation-related remodeling and data from carefully controlled trials in human atrial fibrillation would be of value.
Jules C Hancox; Sheila A Doggrell
Related Documents :
910715 - Atrial fibrillation in the preexcitation syndrome.
19113795 - Role of angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers, and...
439925 - Effects of systemic hypothermia on myocardial metabolism and coronary blood flow in the...
95635 - Characterization of atrial fibrillation in man: studies following open heart surgery.
3826665 - Clinical experience with adenosine for controlled hypotension during cerebral aneurysm ...
3500285 - Tomographic myocardial perfusion scintigraphy in children with kawasaki disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  19     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1465-74     Citation Subset:  IM    
University of Bristol, School of Physiology and Pharmacology, Bristol, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support
//British Heart Foundation

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Short communication: dynamic constraints on the second phase compartment of HIV-infected cells.
Next Document:  Therapeutic potential of new second generation antipsychotics for major depressive disorder.